Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C. Meguid
Operative Outcomes Following Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy (Sbrt) for Borderline Resectable and Locally Advanced Pancreatic Cancer
HPB
Hepatology
Gastroenterology
Related publications
Folfirinox Neoadjuvant Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer - A Retrospective Study
International Journal of Contemporary Medical Research [IJCMR]
Serum Protein Expression and Associations With Conversion to Resectable Status Following Chemotherapy and Stereotactic Body Radiation Therapy in Locally Advanced Pancreatic Adenocarcinoma
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Outcomes With FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer
Journal of Surgical Oncology
Medicine
Surgery
Oncology
Erratum To: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
Annals of Surgical Oncology
Oncology
Surgery
Dosimetric Constraints in Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: Capacity for Dose Escalation
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Neoadjuvant FOLFIRINOX for Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
Oncologist
Cancer Research
Medicine
Oncology
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine
Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advance Pancreatic Cancer (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short- And Long-Term Outcomes
HPB
Hepatology
Gastroenterology
A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Journal of Carcinogenesis & Mutagenesis
